Latest Breaking News On - Company or unicycive - Page 2 : comparemela.com

Unicycive Announces First Quarter 2024 Financial Results And Provides Business Update

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

28.03.2024 - – Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, .

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu

Unicycive Therapeutics (UNCY) Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference